FDA loosens AI oversight: What clinicians need to know about the 2026 guidance
On January 6, 2026, the FDA announced revised guidance that loosens oversight for certain AI-enabled digital health products, most notably clinical decision support (CDS) software. The goal was to cut unnecessary regulation and promote innovation, accelerating time-to-market for tools positioned as clinical assistants rather than autonomous decision-makers.
At first glance, the change looks pragmatic, even overdue. For years, developers and clinicians alike have complained that prior FDA interpretations forced artificial …
FDA loosens AI oversight: What clinicians need to know about the 2026 guidance







![Why physicians must lead the design of artificial intelligence in health care [PODCAST]](https://kevinmd.com/wp-content/uploads/156891f3-d875-411e-9a3e-c50a13997d53-190x100.jpeg)





![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)



![Why weight regain is a predictable biological response after stopping GLP-1s [PODCAST]](https://kevinmd.com/wp-content/uploads/662faf85-c18d-47d3-8970-8f0e4231882f-190x100.jpeg)

